Overview

Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To compare the overall survival of thalidomide- and placebo-treated advanced HCC patients.
Phase:
Phase 3
Details
Lead Sponsor:
TTY Biopharm
Treatments:
Thalidomide